aTyr Pharma's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.27.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.04.
During the past 3 years, the average EBIT per Share Growth Rate was 16.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 39.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 33.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for aTyr Pharma's EBIT per Share or its related term are showing as below:
LIFE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8.1 Med: 33.3 Max: 59.2
Current: 16.2
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of aTyr Pharma was 59.20% per year. The lowest was -8.10% per year. And the median was 33.30% per year.
LIFE's 3-Year EBIT Growth Rate is ranked better than 67.18% of 1307
companies
in the Biotechnology industry
Industry Median: 3.4
vs LIFE: 16.20
aTyr Pharma's EBIT for the
three
months ended in Dec. 2023 was $-15.96 Mil.
aTyr Pharma EBIT per Share Historical Data
The historical data trend for aTyr Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (NAS:LIFE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
aTyr Pharma EBIT per Share Related Terms
Thank you for viewing the detailed overview of aTyr Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 